VAN WIJMEERSCH, Bart

Email Alert RSS Feed

Profile

Full Name
VAN WIJMEERSCH, Bart
Email
bart.vanwijmeersch@uhasselt.be
 
Loading... 5 0 5 0 false
Loading... 6 0 5 0 false

Publications

Refined By:
Type:  Journal Contribution
Date Issued:  [2010 TO 2019]

Results 41-60 of 94 (Search time: 0.004 seconds).

show all
Issue DateTitleContributor(s)TypeCat.
412018Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patientsMONTES DIAZ, Gwendoline; FRAUSSEN, Judith; VAN WIJMEERSCH, Bart; Hupperts, R.; SOMERS, VeerleJournal ContributionA1
422018Walking endurance and perceived symptom severity after a single maximal exercise test in persons with mild disability because of multiple sclerosis.MOUMDJIAN, Lousin; GERVASONI, Elisa; VAN HALEWYCK, Florian; OP 'T EIJNDE, Bert; WENS, Inez; VAN GEEL, Fanny; VAN WIJMEERSCH, Bart; FEYS, Peter; VAN ASCH, PaulJournal ContributionA1
432018Improving fatigue in multiple sclerosis by smartphone-supported energy management: The MS TeleCoach feasibility studyD'hooghe, Marie; Van Gassen, Geert; Kos, Daphne; Bouquiaux, Olivier; Cambron, Melissa; Decoo, Danny; Lysandropoulos, Andreas; VAN WIJMEERSCH, Bart; Willekens, Barbara; Penner, Iris-Katharina; Nagels, GuyJournal ContributionA1
442018Twelve Weeks of Medium-Intensity Exercise Therapy Affects the Lipoprotein Profile of Multiple Sclerosis Patients.JORISSEN, Winde; VANMIERLO, Tim; WENS, Inez; SOMERS, Veerle; VAN WIJMEERSCH, Bart; BOGIE, Jeroen; Remaley, Alan; OP 'T EIJNDE, Bert; HENDRIKS, JeromeJournal ContributionA1
452018Multidisciplinary data infrastructures in multiple sclerosis: Why they are needed and can be done!PEETERS, Liesbet; van Munster, Caspar E.; VAN WIJMEERSCH, Bart; BRUYNDONCKX, Robin; LAMERS, Ilse; HELLINGS, Niels; POPESCU, Veronica; Thalheim, Christoph; FEYS, PeterJournal ContributionA1
462017Does including the full CVLT-II and BVMT-R improve BICAMS? Evidence from a Belgian (Dutch) validation study.Costers, Lars; Gielen, Jeroen; Eelen, Piet L.; Van Schependom, Jeroen; Laton, Jorne; Van Remoortel, Ann; VANZEIR, Ellen; VAN WIJMEERSCH, Bart; Seeldrayers, Pierrette; Haelewyck, Marie-Claire; D'Haeseleer, Miguel; D'hooghe, Marie-Beatrice; Langdon, Dawn; Nagels, GuyJournal ContributionM
472017Comparative clinical efficacy of alemtuzumab and ocrelizumab in patients with relapsing-remitting multiple sclerosis: Number needed to treat analysesComi, G.; Boster, A.; Alroughani, R.; Berkovich, R.; Izquierdo, G.; Kantor, D.; Laganke, C.; Limmroth, V.; Macdonell, R.; Moreau, T.; Sharrack, B.; Wiendl, H.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Melanson, M.; Freedman, M. S.Journal ContributionM
482017Teri-DYNAMIC: Exploring the impact of teriflunomide on immune cell population size, receptor repertoire, and function in patients with RRMSWiendl, Heinz; Gross, Catharina C.; Eschborn, Melanie; Weisser, Linda; Posevitz-Fejfar, Anita; Schulte-Mecklenbeck, Andreas; VAN WIJMEERSCH, Bart; Hupperts, Raymond; Brette, Sandrine; Turner, Timothy J.; Bar-Or, Amit; Klotz, LuisaJournal ContributionM
492017Cytomegalovirus infection exacerbates autoimmune mediated neuroinflammationVANHEUSDEN, Marjan; BROUX, Bieke; Welten, Suzanne P. M.; PEETERS, Liesbet; Panagioti, Eleni; VAN WIJMEERSCH, Bart; SOMERS, Veerle; STINISSEN, Piet; Arens, Ramon; HELLINGS, NielsJournal ContributionA1
502017Cytotoxic CD4+T Cells Drive Multiple Sclerosis ProgressionPEETERS, Liesbet; VANHEUSDEN, Marjan; SOMERS, Veerle; VAN WIJMEERSCH, Bart; STINISSEN, Piet; BROUX, Bieke; HELLINGS, NielsJournal ContributionA1
512017Does including the full CVLT-II and BVMT-R improve BICAMS? Evidence from a Belgian (Dutch) validation studyCosters, Lars; Gielen, Jeroen; Eelen, Piet L.; van Schependom, Jeroen; Laton, Jorne; Van Remoortel, Ann; VANZEIR, Ellen; VAN WIJMEERSCH, Bart; Seeldrayers, Pierrette; Haelewyck, Marie-Claire; D'Haeseleer, Miguel; D'hooghe, Marie-Beatrice; Langdon, Dawn; Nagels, GuyJournal ContributionA1
522016Design of two phase III open-label trials evaluating ocrelizumab in patients with relapsing-remitting multiple sclerosis and suboptimal response to disease-modifying treatmentBermel, R.; Comi, G.; Eralinna, J. -P.; Leist, T. P.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Bernasconi, C.; Buffels, R.; Csoboth, C.; Han, J.; Musch, B.; Vermersch, P.Journal ContributionM
532016Durable improvement in clinical outcomes in treatmentnaive patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a to alemtuzumab (care-MS I extension study 4-year follow-up)Oreja-Guevara, C.; Alroughani, R.; Brassat, D.; Boyko, A. N.; McCombe, P.; Steingo, B.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E.; Vermersch, P.Journal ContributionM
542016Effects of teriflunomide treatment on the CD4(+) T-cell receptor repertoire in patients with relapsing-remitting MSKlotz, Luisa; Lindner, Maren; Gross, Catherina C.; Eschborn, Melanie; Posevitz-Fejfar, Anita; Schulte-Mecklenbeck, Andreas; Meuth, S. G.; VAN WIJMEERSCH, Bart; Hupperts, Raymond; Maeurer, M.; Stangel, M.; Lang, M.; Tackenberg, B.; Lysandropoulos, A.; Decoo, D.; Eveslage, M.; Turner, Timothy J.; Jagerschmidt, A.; Bar-Or, Amit; Wiendl, HeinzJournal ContributionM
552016Durable reduction in MRI disease activity with alemtuzumab in treatment-naive patients with active relapsing-remitting multiple sclerosis: 6-year follow-up of the CARE-MS I studyArnold, D. L.; Barnett, M.; Comi, G.; Giovannoni, G.; Pelletier, D.; Rovira, A.; Schippling, S.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Traboulsee, A.Journal ContributionM
562016Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).Coles, A. J.; Boyko, A. N.; Cohen, J. A.; De Seze, J.; Fox, E. J.; Havrdova, E.; Hartung, H. -P.; Inshasi, J. S.; McCombe, P.; Selmaj, K. W.; Vermersch, P.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E.; Montalban, X.Journal ContributionM
572016Brain atrophy by automated MRI reading in long-term natalizumab treated patients: Real world data suggests brain atrophy rates in range of healthy individualsHorakova, Dana; Uher, T.; Vaneckova, M.; Krasensky, J.; Seidl, Z.; van Pesch, V.; Lysandropoulos, A.; VAN WIJMEERSCH, Bart; Ribbens, A.; van Hecke, W.; Dong, Q.; Farkas, M.; Hyde, R.; Koendgen, H.Journal ContributionM
582016Age-Associated B Cells with Proinflammatory Characteristics Are Expanded in a Proportion of Multiple Sclerosis PatientsCLAES, Nele; FRAUSSEN, Judith; VANHEUSDEN, Marjan; HELLINGS, Niels; STINISSEN, Piet; VAN WIJMEERSCH, Bart; Hupperts, Raymond; SOMERS, VeerleJournal ContributionA1
592016B cells of multiple sclerosis patients induce autoreactive proinflammatory T cell responsesFRAUSSEN, Judith; CLAES, Nele; VAN WIJMEERSCH, Bart; VAN HORSSEN, Jack; STINISSEN, Piet; Hupperts, Raymond; SOMERS, VeerleJournal ContributionA1
602016Upper Limb Rehabilitation in People With Multiple Sclerosis: A Systematic ReviewLAMERS, Ilse; MARIS, Anneleen; SEVERIJNS, Deborah; Dielkens, Wouter; Geurts, Sander; VAN WIJMEERSCH, Bart; FEYS, PeterJournal ContributionA1
show all